Disease Domain | Count |
---|---|
Neoplasms | 6 |
Nervous System Diseases | 2 |
Infectious Diseases | 2 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Chemical drugs | 2 |
Biological products | 1 |
Target |
Mechanism NMDA receptor modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HDAC inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Start Date28 Feb 2024 |
Sponsor / Collaborator |
Start Date08 Jan 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tllsh-2910 ( NMDA receptor ) | Friedreich Ataxia More | Phase 3 |
J-4 | Alzheimer Disease More | Preclinical |
Ametantrone ( Top II ) | Neoplasms More | Preclinical |
IY-2A ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |
J-21475 ( Aurora A x FLT3 ) | Neoplasms More | Preclinical |